<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>G Paper Bulletin</title>
    <link rel="stylesheet" href="/static/G-Paper-Bulletin%20css/paper_detail%20style.css">
</head>
<body>
    <h1>Paper 36 Details</h1>

    <div class="container">
        <div class="text-column">
            <p>
                <strong>Title:</strong> Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout
                <!-- <strong>Title:</strong> Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout -->
            </p>
            <p>Author and year: P. E. Lipsky (2014)</p>
            <p>Plot types:<br> None</p>
            <p>Relevance: (rating  1) What is the details about pegloticase immunogencity?</p>
            <p>Innovation: (rating  0) None</p>
            <p>Economic Value: (rating  0) None</p>
            <p><a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C23&amp;q=Pegloticase+immunogenicity%3A+the+relationship+between+efficacy+and+antibody+development+in+patients+treated+for+refractory+chronic+gout&amp;btnG=" target="_blank">Google scholar link</a></p>
            <p><a href="https://link.springer.com/article/10.1186/ar4497" target="_blank">Paper link</a></p>
            <div class="paper-links" data-topic-id="2" data-paper-id="36"></div>
            
                <p>
                    <a href="/g-paper-bulletin/topic/2/year.html">Back to Topic Pegloticase Gout Treatment</a>
                </p>
                        
        </div>
        <div class="image-column">
            <ul>
                <div class="citation-box">
                    <p>
                        IEEE Citation: <span id="citation-content" class="clickable" onclick="copyCitation()"> P. E. Lipsky, L. H. Calabrese, A. Kavanaugh, J. S. Sundy, D. Wright, M. Wolfson, and M. A. Becker, “Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout,” <em>Arthritis Res. Ther.</em>, vol. 16, Apr. 2014, pp. 1–8. </span>
                    </p>      
                    <p>G Title: None</p>
                </div>
                
                    <li>
                        <a href="/g-paper-bulletin/topic/2/year.html"><img src="/static/G-Paper-Bulletin%20image/2%20Pegloticase%20Gout%20Treatment/2_36_1.png" style="width: 300px; height: auto;"></a>
                    </li>
                
                    <li>
                        <a href="/g-paper-bulletin/topic/2/year.html"><img src="/static/G-Paper-Bulletin%20image/2%20Pegloticase%20Gout%20Treatment/2_36_2.png" style="width: 300px; height: auto;"></a>
                    </li>
                
            </ul>
        </div>
    </div>
    <script src="/static/G-Paper-Bulletin%20js/copy_citation.js"></script>
    <script src="/static/G-Paper-Bulletin%20js/cross_reference.js"></script>
</body>
</html>